Literature DB >> 12176221

Biodegradable microparticles for the mucosal delivery of antibacterial and dietary antigens.

Elias Fattal1, Sophie Pecquet, Patrick Couvreur, Antoine Andremont.   

Abstract

Mucosal administration of antigen is known to be appropriate for vaccine purposes as well as tolerance induction. Biodegradable poly(DL-lactide-co-glycolide) (PLGA) microparticles were used to deliver both antibacterial phosphorylcholine (PC) and dietary antigen beta lactoglobulin (BLG) by mucosal route. In a first study, the protective immunity elicited by intragastric vaccination with PC encapsulated in microparticles was evaluated in a mouse model against intestinal infection by Salmonella typhimurium and pulmonary infection by Streptococcus pneumoniae. A significant rise in anti-PC immunoglobulin A (IgA) titers, as measured by an enzyme-linked immunosorbent assay, was observed in the intestinal secretions after oral immunization with PC-loaded microparticles compared with the titers of mice immunized with free PC-thyr or blank microparticles. This antibody response correlated with a highly significant resistance to oral challenge by S. typhimurium. IgA in pulmonary secretion were not able to protect against S. pneumoniae infection. BALB/c mice were, therefore, immunized intranasally (i.n.). Immunization was followed by a rise in anti-PC IgA and IgG titers in serum and in pulmonary secretions by both free and encapsulated PC-Thyr. The survival rates were 91 and 76% in the two groups of mice, respectively. In a second study and in order to prevent allergy against milk by inducing oral tolerance, one of the major allergenic milk protein, BLG was entrapped into microparticles. Oral administration of microparticles containing BLG reduced significantly (by 10000) the amount of protein necessary to decrease both specific anti BLG IgE and DTH response. These studies demonstrate the ability of microparticles to induce both mucosal immunity and oral tolerance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12176221     DOI: 10.1016/s0378-5173(02)00181-3

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

Review 1.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 2.  Past, present, and future technologies for oral delivery of therapeutic proteins.

Authors:  Rajesh Singh; Shailesh Singh; James W Lillard
Journal:  J Pharm Sci       Date:  2008-07       Impact factor: 3.534

3.  Synthesis and characterization of thiolated carboxymethyl chitosan-graft-cyclodextrin nanoparticles as a drug delivery vehicle for albendazole.

Authors:  Ghazaleh Alamdarnejad; Alireza Sharif; Shahrouz Taranejoo; Mohsen Janmaleki; Mohammad Reza Kalaee; Mohsen Dadgar; Mazyar Khakpour
Journal:  J Mater Sci Mater Med       Date:  2013-05-12       Impact factor: 3.896

Review 4.  Nanotechnology: intelligent design to treat complex disease.

Authors:  Patrick Couvreur; Christine Vauthier
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.580

Review 5.  Rational design for multifunctional non-liposomal lipid-based nanocarriers for cancer management: theory to practice.

Authors:  Sabrina Valetti; Simona Mura; Barbara Stella; Patrick Couvreur
Journal:  J Nanobiotechnology       Date:  2013-12-10       Impact factor: 10.435

6.  Plant-derived protein bodies as delivery vehicles for recombinant proteins into mammalian cells.

Authors:  Jennifer Schwestka; Marc Tschofen; Stefan Vogt; Sylvain Marcel; Johannes Grillari; Marianne Raith; Ines Swoboda; Eva Stoger
Journal:  Biotechnol Bioeng       Date:  2020-01-30       Impact factor: 4.395

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.